Clinical Trial Update: Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II, multicenter, non-randomized, single-arm study evaluating disitamab vedotin in combination with platinum chemoth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent | Phase 2 | Status: RECRUITING